Tollys
  • About Us
    • Company
    • Board of Directors
    • Management
    • Scientific Advisory Board
  • Science
    • Immuno-oncology
    • TLR3 Science
    • Publications & Posters
  • Product
    • TL-532
    • Intellectual property
  • Pipeline
    • TLR3+ Cancers
  • News
  • Careers
  • Contact
Select Page

Synthetic TLR-3 ligands

by Marielle Féret | Feb 1, 2022 | Publications

ESMO – December 2021 – Presented by Dr Bettina Werle

Discovery process and in vitrobiological characterization of rationally designed TL-532 Toll-like Receptor 3 (TLR3) agonist as anti-cancer molecule

by Marielle Féret | Feb 1, 2022 | Publications

OTS – September 2021 – Dr Marc Bonnin

First Rationally Designed TLR3 Agonist “TL-532”Induces Tumor Specific Apoptosis, Microenvironment Switch and Immune Stimulation, Leading to Life-long Anti-tumor Auto-vaccination

by Marielle Féret | Feb 1, 2022 | Publications

OTS – September 2021 – Dr Sylvain Thierry

First rationally designed Toll-like Receptor 3 agonist “TL-532”induces apoptosis specific of tumor cells and long-lasting anti-tumor Immunity

by Marielle Féret | Feb 1, 2022 | Publications

EACR – June 2021 – Dr Sylvain Thierry

Discovery process and in vitrobiological characterization of rationally designed TL-532 Toll-like Receptor 3 (TLR3) agonist as anti-cancer molecule

by Marielle Féret | Feb 1, 2022 | Publications

EACR – June 2021 – Dr Marc Bonnin

TL-532, the first rationally designed TLR3 agonist creates long-lasting tumor specific immunity in vivo

by Marielle Féret | Jan 31, 2022 | Publications

Sting & TLR-targeted therapies – May 2021 – Presented by Dr Bettina Werle

« Older Entries

Recent Posts

  • AACR 2022: Tollys releases new preclinical data demonstrating lifelong potent anti-tumor immunity of TL-532
  • Tollys and Gustave Roussy enter into new research agreement
  • Synthetic TLR-3 ligands
  • Discovery process and in vitrobiological characterization of rationally designed TL-532 Toll-like Receptor 3 (TLR3) agonist as anti-cancer molecule
  • First Rationally Designed TLR3 Agonist “TL-532”Induces Tumor Specific Apoptosis, Microenvironment Switch and Immune Stimulation, Leading to Life-long Anti-tumor Auto-vaccination

Recent Comments

    Archives

    • March 2022
    • February 2022
    • January 2022
    • December 2021
    • June 2021
    • May 2021
    • April 2021
    • March 2021
    • February 2021
    • October 2020
    • July 2020
    • May 2020
    • December 2019
    • November 2019
    • August 2018
    • June 2016
    • January 2015
    • September 2012
    • March 2011
    • December 2007
    • August 2007
    • April 2006
    • September 1991
    • July 1980

    Categories

    • News
    • Publications

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    Design by Small Stories ©2019